Home › Funds › FISHMAN JAY A LTD/MI › ARQT
FISHMAN JAY A LTD/MI position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
FISHMAN JAY A LTD/MI reported holding 597,115 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$15.8M, representing 1.27% of its reported portfolio and ranking #18 among its reported holdings. FISHMAN JAY A LTD/MI has disclosed ARQT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How FISHMAN JAY A LTD/MI's ARQT position evolved
FISHMAN JAY A LTD/MI first disclosed a stake in ARQT in Q3 2023 at 87,000 shares (US$462K). The position peaked in Q4 2025 at 564,650 shares, worth US$16.4M. Across 13 filings, FISHMAN JAY A LTD/MI increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 597,115 shares valued at US$15.8M. Notable position changes include a 39% trim in Q4 2023 (shares rose 207% over the following quarter), a 323% increase in Q1 2024 (shares fell 6% over the following quarter), a 55% increase in Q2 2024 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 87.00K | $461.97K | New |
| Q4 2023 | 53.00K | $171.19K | Reduce |
| Q1 2024 | 224.30K | $2.22M | Add |
| Q2 2024 | 346.60K | $3.22M | Add |
| Q3 2024 | 418.00K | $3.89M | Add |
| Q4 2024 | 536.40K | $7.47M | Add |
| Q1 2025 | 533.15K | $8.34M | Reduce |
| Q2 2025 | 556.15K | $7.80M | Add |
| Q3 2025 | 565.65K | $10.66M | Add |
| Q4 2025 | 564.65K | $16.40M | Hold |
| Q1 2026 | 566.73K | $13.35M | Hold |
| Q2 2026 | 595.00K | $15.60M | Add |
| Q3 2026 | 597.12K | $15.78M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Simplify Asset Management Inc. 865.86K sh · $22.88M · Q3 2026
More on FISHMAN JAY A LTD/MI
FAQ
How long has FISHMAN JAY A LTD/MI held ARQT?
FISHMAN JAY A LTD/MI has disclosed ARQT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is FISHMAN JAY A LTD/MI's current position in ARQT?
As of Q3 2026, FISHMAN JAY A LTD/MI holds 597.12K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $15.78M, representing 1.27% of its reported portfolio and ranking #18.
Has FISHMAN JAY A LTD/MI been buying or selling ARQT?
In the latest 13F filing (Q3 2026), FISHMAN JAY A LTD/MI held unchanged its position in ARQT. The position peaked in Q4 2025 at 564.65K shares.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.